Trilipix is a drug owned by Abbvie. It contains the active ingredient choline fenofibrate and was first authorised for market use on 15 December, 2008. The drug is available in capsule, delayed release;oral dosage forms.
The generic versions of Trilipix are expected to be released after 07 January, 2025. This release date coincides with the expiration of its last patent, US7259186.
Trilipix, containing choline fenofibrate, is used to treat high cholesterol and high triglyceride levels. It helps to reduce the risk of atherosclerosis and related heart diseases by reducing the amount of cholesterol and other types of fat in the blood.
Trilipix holds a total of 1 patent. The latest patent, titled 'Salts of fenofibric acid and pharmaceutical formulations thereof', is due to expire on 2025-01-07, potentially allowing for the release of Trilipix generics. Below are the details of the patent: